Indian pharmaceutical shares slipped after US President Donald Trump announced a 100% import tariff on pharmaceutical drugs effective 1 October.
-
Sun Pharmaceutical Industries traded at RS 1579.35, down 48.65 points (2.99%) from its previous close of RS 1628.00 on the BSE. The stock opened at RS 1590.60 and touched a high of RS 1602.90 and a low of RS 1547.25. Total volume so far: 2,46,150 shares.
-
Lupin stood at RS 1927.00, slipping 34.45 points (1.76%) from its last close of RS 1961.45. It opened at RS 1923.30, with an intraday high of RS 1950.65 and low of RS 1912.90. Total volume: 20,214 shares.
-
Dr. Reddy’s Laboratories traded at RS 1255.25, down 19.55 points (1.53%) from its previous close of RS 1274.80. The stock opened at RS 1248.10 and recorded a high of RS 1277.95 and low of RS 1245.30. Total volume: 75,324 shares.
The sudden US tariff hike targets branded and patented drugs, unsettling Indian pharma counters even though most of their US revenue comes from generics. The US remains India’s largest pharmaceutical export market, accounting for nearly 35% of total exports—valued at about $10 billion in FY25.